Browse the evidence

Substituting protease inhibitors with other antiretroviral drugs (such as nevirapine) can mitigate metabolic abnormalities like dyslipidemia and glucose intolerance, though reversal of fat redistribution is uncertain.

If you develop metabolic issues on your current HIV meds, ask your doctor about switching to a non-PI regimen (like nevirapine). This may fix your cholesterol and blood sugar problems without necessarily reversing the body shape changes, and it can still keep the virus suppressed.

Exogenous administration of spermidine or spermine improves glucose homeostasis, insulin sensitivity, and reduces adiposity in diet-induced obesity mouse models.

Current research indicates that spermidine and spermine supplementation may improve metabolic health in obese individuals, particularly by enhancing insulin sensitivity and reducing fat accumulation. However, most evidence comes from animal models. While human trials show increased blood levels with supplementation, direct metabolic benefits in humans are not yet fully established. Consult a healthcare provider before starting supplementation, especially if you have existing metabolic conditions.

Small-molecule ago-allosteric modulators of the GLP-1 receptor stimulate glucose-dependent insulin secretion and potentiate endogenous GLP-1 effects without altering GLP-1 potency, offering a potential pathway for orally active diabetes treatments.

This research describes a new class of small molecules that activate the GLP-1 receptor. Currently, these are experimental compounds tested in lab settings (cells and animal tissues). They stimulate insulin release in a glucose-dependent manner, similar to the natural hormone GLP-1, but via a different binding mechanism (allosteric). This is a foundational discovery for developing oral diabetes medications, but no such drug is currently available for human use based on this text.

Activation of Sirt1 via exercise or Sirt1-activating compounds (e.g., resveratrol, SRT3025) delays vascular aging and reduces atherosclerosis by enhancing antioxidant enzyme activity and improving endothelial nitric oxide synthase (eNOS) function.

Engage in regular physical exercise, which naturally boosts Sirt1 activity by increasing NAD+ levels. This helps maintain vascular health and may delay age-related cardiovascular decline. While supplements like resveratrol are marketed for this purpose, human evidence is inconsistent, making exercise the most reliable intervention.

Genetic deletion or silencing of the adaptor protein p66Shc reduces oxidative stress, improves endothelial function, and reduces stroke size in animal models, but may increase infarct size in specific myocardial ischemia-reperfusion contexts.

Current research suggests that targeting p66Shc could help prevent stroke and vascular aging, but it is not yet a viable therapeutic strategy due to conflicting effects on heart tissue. Focus on proven lifestyle factors like exercise and diet to manage oxidative stress.

Gut microbiota-derived lipopolysaccharides (LPS) and peptidoglycan (PGN) promote NAFLD progression by activating hepatic Toll-like receptors (TLR4, TLR2, NOD1/2), triggering inflammatory cytokine release and steatosis.

Your liver health is heavily influenced by what lives in your gut. An unhealthy diet can disrupt gut bacteria, allowing harmful bacterial parts (like LPS) to leak into your bloodstream and inflame your liver. Prioritizing a diet that supports a healthy gut microbiome (e.g., high fiber) may help reduce this inflammatory load on the liver.

Gut microbiota-derived metabolites, specifically Short-Chain Fatty Acids (SCFAs) like butyrate, acetate, and propionate, ameliorate NAFLD by inhibiting histone deacetylases (HDACs) and activating G-protein coupled receptors (GPR41, GPR43).

Eating soluble dietary fibers feeds gut bacteria to produce Short-Chain Fatty Acids (SCFAs) like butyrate. These metabolites help reduce liver inflammation and fat accumulation by regulating gene expression and immune responses. Focus on fiber-rich foods rather than isolated SCFA supplements.

Gut microbiota-derived Trimethylamine-N-oxide (TMAO) and secondary bile acids modulate NAFLD progression through regulation of bile acid metabolism, insulin resistance, and hepatic inflammation.

The conversion of dietary nutrients (choline, carnitine) by gut bacteria into TMA, and subsequently TMAO in the liver, influences bile acid metabolism and insulin resistance. Managing dietary intake of these precursors and supporting healthy bile acid signaling (via secondary bile acids) may help manage NAFLD.

Gut microbiota dysbiosis, characterized by elevated pathobionts (e.g., Proteobacteria, Enterobacteriaceae) and depleted beneficial bacteria (e.g., Faecalibacterium, Bifidobacterium), is associated with gestational diabetes mellitus (GDM) and postpartum glucose intolerance, potentially serving as a predictive biomarker for type 2 diabetes.

If you have or had GDM, your gut bacteria may look different from those without GDM, resembling the profile of type 2 diabetes. While this doesn't mean you are doomed, it suggests that maintaining a healthy gut through diet and lifestyle might be a key strategy for preventing type 2 diabetes after pregnancy. Consult your doctor about monitoring your metabolic health.

Gut microbiota dysbiosis in GDM involves elevated lipopolysaccharide (LPS) production and translocation, leading to low-grade inflammation and insulin resistance.

High levels of certain gut bacteria (pathobionts) can lead to inflammation and insulin resistance. While this is a key mechanism in GDM, it is not yet clear if fixing the microbiota alone will cure GDM. Focus on overall metabolic health.

Thyroid dysfunction (both hypo- and hyperthyroidism) is bidirectionally associated with metabolic syndrome components, where thyroid hormones regulate metabolic rate, adiposity, and glucose/lipid metabolism, while adiposity and insulin resistance reciprocally affect thyroid function via leptin and inflammatory cytokines.

If you have metabolic syndrome or obesity, your thyroid health is likely affected, and vice versa. High TSH is associated with higher risk of metabolic syndrome components like high blood pressure, triglycerides, and insulin resistance. Conversely, losing weight and improving insulin sensitivity can improve thyroid function markers. Do not assume treating thyroid levels alone will resolve metabolic issues; address adiposity and insulin resistance concurrently.

Dysregulation of specific microRNAs (miRNAs) in adipose tissue, pancreas, liver, and muscle contributes to the pathogenesis of obesity and related metabolic diseases by altering gene expression involved in energy balance, insulin signaling, and inflammation.

Obesity involves complex biological regulation beyond just calories in vs. calories out. Specific microRNAs in your fat, liver, and muscle cells can become dysregulated, contributing to insulin resistance and inflammation. While lifestyle changes remain foundational, understanding this biological layer explains why obesity can be stubborn and why future treatments may target these specific molecular pathways.

Circulating microRNAs (miRNAs) found in plasma and other body fluids can serve as biomarkers for obesity and metabolic diseases, and may act as endocrine signaling molecules mediating inter-organ communication.

Blood tests may soon be able to detect specific microRNAs that indicate metabolic stress or obesity-related risks before clinical symptoms appear. This could lead to earlier interventions. Additionally, fat tissue may release these molecules to communicate with other organs, influencing metabolism system-wide.

Specific microRNAs (e.g., miR-143, miR-145, miR-27a, miR-130a) regulate adipogenesis (fat cell formation) and insulin sensitivity, with some promoting and others inhibiting fat cell differentiation and glucose homeostasis.

The formation of new fat cells is tightly controlled by specific microRNAs. Some miRNAs encourage fat storage (like miR-143), while others prevent it (like miR-27a). This biological regulation explains why fat distribution and insulin sensitivity vary significantly between individuals.

Gut microbiota alterations in obesity contribute to chronic low-grade inflammation through increased lipopolysaccharide (LPS) translocation, which triggers immune responses and insulin resistance.

High levels of bacterial toxins (LPS) can leak into your bloodstream if your gut barrier is compromised, causing inflammation and insulin resistance. A diet rich in fiber and fermented foods may support gut barrier integrity.

Treatment with trans-10,cis-12 conjugated linoleic acid (CLA) reduces triglyceride accumulation in human preadipocytes by decreasing insulin-stimulated glucose uptake, glucose oxidation, and oleic acid uptake/oxidation, while downregulating PPARγ expression and target genes.

This research indicates that a specific form of CLA (trans-10,cis-12) can reduce fat storage in human fat cells by slowing down how they process sugars and fats. However, this was done in a lab dish, not in people. Do not expect this to cause weight loss on its own. It suggests that not all CLA supplements are created equal, and some may even work against fat loss goals by reducing metabolic activity in fat cells.

Caloric restriction extends lifespan and delays age-related decline by activating SIRT1, which deacetylates and activates eNOS to improve vascular function and reduce oxidative stress.

To leverage this mechanism, consider implementing caloric restriction (e.g., reducing intake by 10-20% without malnutrition) to potentially activate SIRT1. This may improve vascular function and reduce oxidative stress, contributing to healthier aging. Consult a healthcare provider before making significant dietary changes.

Physical exercise increases cerebrospinal fluid and plasma levels of Orexin-A, which may contribute to exercise-induced hippocampal neurogenesis and cognitive benefits.

Engage in regular physical exercise. Beyond physical fitness, this increases Orexin-A levels, which may support brain health, neurogenesis, and cognitive performance by crossing the blood-brain barrier.

Skeletal muscle releases alpha-sarcoglycan-positive extracellular vesicles (EVs) containing muscle-specific microRNAs (myomiRs) into the bloodstream, serving as a mechanism for inter-organ communication and adaptation to exercise.

This research highlights that aerobic exercise triggers your muscles to release specific signaling molecules (miRNAs) packaged in protective vesicles. These signals likely help regulate muscle health and adaptation. To leverage this, prioritize consistent aerobic exercise (e.g., running, cycling) which has been shown to modulate these specific muscle-derived signals, rather than assuming all exercise types produce identical molecular benefits.

Soy isoflavones (specifically genistein and daidzein) reduce adipose tissue and improve lipid profiles in rodents through estrogen receptor (ER) and PPAR-mediated pathways, but these effects are highly dependent on sex, age, and dosage, with high pharmacological doses often required to achieve in vitro-relevant concentrations in vivo.

Soy isoflavones are not a reliable weight-loss tool for humans at typical dietary or supplemental doses. While rodent studies show fat reduction at very high, pharmacological doses, these effects are inconsistent, sex-specific, and sometimes promote fat gain in young males. The concentrations needed to see benefits in cell cultures are far higher than what humans achieve through diet. Focus on whole soy foods for general health, but do not rely on isoflavone supplements for obesity treatment.

Testosterone replacement therapy in older men with hypogonadism causes a modest, predictable increase in serum PSA levels (average ~0.3-0.5 ng/mL) but does not appear to increase the incidence of clinically overt prostate cancer in existing short-to-medium term randomized controlled trials.

If you are an older man with clinically low testosterone, TRT will likely raise your PSA levels slightly (by about 0.3-0.5 ng/mL). This is a normal physiological response, not a sign of cancer. Current studies do not show that TRT increases the risk of developing prostate cancer, although long-term data is still needed. You should undergo regular PSA monitoring; a rise of more than 1.4 ng/mL from your baseline warrants further urological evaluation, but small increases are expected.

Astragaloside IV (AS-IV), a saponin in Astragalus, reduces blood glucose and insulin resistance by modulating intestinal microbiota to increase butyric acid and activating PI3K/AKT and AMPK/SIRT1 signaling pathways.

Astragaloside IV (AS-IV), a key compound in Astragalus, may help lower blood sugar and improve insulin sensitivity. It works by changing gut bacteria to produce more butyric acid and by activating specific cellular pathways that help cells use insulin better. This suggests Astragalus may be beneficial for managing T2DM.

Dietary supplementation with wheat-derived arabinoxylan oligosaccharides (AXOS) reduces body weight gain and fat mass in diet-induced obese mice by increasing satietogenic gut peptides (PYY and GLP-1) and reducing metabolic endotoxemia.

In this mouse study, wheat-derived arabinoxylan oligosaccharides (AXOS) helped reduce weight gain and fat mass when added to a high-fat diet. This effect was linked to increased levels of satiety hormones (PYY and GLP-1) and reduced inflammation. While promising, this is animal research, so human application requires further validation.

AXOS supplementation improves gut barrier function and reduces metabolic endotoxemia in obese mice by upregulating tight junction proteins (ZO1 and claudin 3).

AXOS may help improve gut barrier integrity in obese individuals, potentially reducing inflammation associated with high-fat diets. This is based on mouse models and requires human confirmation.